
https://www.science.org/content/blog-post/big-pharma-killing-startup-companies
# Is Big Pharma Killing Startup Companies? (February 2011)

## 1. SUMMARY
This commentary covers venture capitalist Kevin Kinsella's argument that "predatory business practices" by Big Pharma were then damaging the life sciences venture capital ecosystem and pushing biotech ventures toward extinction. He cited short-sighted, "brass-knuckle negotiating tactics" and heads-I-win, tails-you-lose deal structures that kept risk on smaller companies until money appeared, at which point the larger partner captured most of the gains. Kinsella traced this dynamic to a confluence of forces after the post-2000 tech/biotech bubble burst and the 2008 mortgage meltdown, which wiped out most Wall Street biotech-focused banking talent through layoffs and firm closures (e.g., Hambrecht & Quist, Robertson Stephens, Montgomery Securities). With few "serious" banks remaining to serve life sciences startups or underwrite biotech IPOs, exit options narrowed, leaving small companies more dependent than ever on Big Pharma deals. Adding to the imbalance, pharma companies were hiring those laid-off biotech bankers who brought "inside baseball" knowledge of how to wring concessions from venture-backed biotechs, tightening the squeeze on startups.

## 2. HISTORY
After the article's publication, the biotech-pharma ecosystem evolved significantly rather than collapsing:
- **VC and startup rebound**: The decade following 2011 saw substantial venture capital reinvestment in biotech and an acceleration of company formation. Major venture firms (Atlas Venture, Third Rock, Versant, ARCH) raised successive dedicated biotech/healthcare funds, and new platform companies (e.g., Moderna founded 2010, Alnylam ongoing) matured, belying the "extinction" prediction.
- **Capital markets reopening**: Biotech IPOs surged in multi-wave cycles. The NASDAQ Biotech Index rose substantially from 2011 lows, with numerous offerings through 2013–2015, the 2018–2019 upturn, and a historic peak in 2020–2021. Banks including Goldman Sachs, Morgan Stanley, J.P. Morgan, and specialized boutiques (Leerink, Evercore) built dedicated healthcare investment banking teams, contradicting the claim that no "serious" banks remained.
- **Partnership and M&A dynamics**: Pharma continued large acquisitions of biotechs (e.g., Gilead/Kite 2017; BMS/Celgene 2019; AstraZeneca/Alexion 2020; Merck/Prometheus 2023), but many smaller companies retained substantial value and negotiating leverage. Alliances evolved toward option-based and risk-sharing structures (e.g., AbbVie–Calico, J&J–Bristol Myers alliances), not uniformly predatory.
- **Regulatory successes**: Novel modalities matured; for example, checkpoint inhibitors (pembrolizumab approved 2014), CAR-T (tisagenlecleucel 2017), gene therapies (Luxturna 2017; Zolgensma 2019), and mRNA vaccines (Pfizer-BioNTech and Moderna COVID-19 vaccines 2020). These were often advanced by biotech startups that partnered or later commercialized successfully.
- **Public policy shifts**: U.S. policy encouraged innovation (21st Century Cures Act 2016; accelerated approval pathways). Antitrust scrutiny tempered some "brass-knuckle" tactics, while R&D collaborations diversified beyond traditional licensing.
- **What didn't happen**: The ecosystem did not shrink to a handful of defiant "go it alone" companies. Instead, a robust middle tier of public biotechs emerged, venture creation accelerated, and multiple exit paths (IPO, acquisition, SPACs, crossover rounds) normalized by the mid-2010s and beyond.

## 3. PREDICTIONS
- **Claim**: Fewer small companies would survive, and the remainder would disproportionately consist of "outfits trying to go it alone."
  - **Outcome**: This did not materialize. Biotech VC financing and company creation grew substantially; alliances and M&A expanded; far from going it alone, most startups pursued partnerships or strategic exits.
- **Claim**: IPO exits would remain constrained, with "not much of an IPO exit any more."
  - **Outcome**: Biotech IPOs rebounded strongly starting around 2013 and cycled through multiple peaks (2015, 2018–2019, 2020–2021), with numerous $100M+ offerings and dedicated healthcare banking teams.
- **Claim**: Pharma's predatory practices would push biotech "almost to the point of extinction."
  - **Outcome**: The sector recovered and expanded. Major scientific advances emerged from venture-backed biotechs, many via pharma partnerships; cash reserves in biotech grew through 2021; and new platform companies thrived.
- **Implicit prediction**: That banks serving life sciences startups would not recover.
  - **Outcome**: Investment banks rebuilt healthcare/biotech franchises; specialized boutiques scaled, and IPO underwriting normalized after 2012–2013.

## 4. INTEREST 
Rating: **6/10**
A relevant snapshot of the post-2008 biotech capital crunch that correctly highlighted structural imbalances but overstated the long-term collapse risk; the sector rebounded more robustly than predicted.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20110224-big-pharma-killing-startup-companies.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_